Marizomib for Patients with Ependymoma

A study for adults with recurrent ependymoma.

Objective

National Cancer Institute (NCI) researchers are conducting a study of patients with ependymoma.

Ependymomas are rare cancerous tumors that grow in the central nervous system. This study will test if the drug marizomib slows or stops the spread of cancer cells in the brain or spine. Results from this research study may help doctors to control these tumor types.

What the study involves:

- Physical and neurological examination
- EKG to evaluate the heart
- Patient questionnaire about health and symptoms
- MRIs and neurological function tests
- Study of tumor tissue from prior surgeries
- Your samples used for a health evaluation
- Receive drug marizomib for up to 24 cycles. Each cycle is four weeks.

You can participate if you:

- Are age 18 or older
- Are diagnosed with an ependymoma that has returned
- Have been treated with standard therapies
- Are not pregnant or breastfeeding

Questions?

Contact us at (240) 760-6010 or NCINOBReferrals@mail.nih.gov

clinicaltrials.gov ID: NCT03727841